Y.YuJ.AsensoJ.XiaoF.et al (2016b)
At TrimRx, we believe that sustainable weight loss should be achieved through science, empathy, and a transparent approach
GLP-1 MARKET, BY ACTIVE COMPOUND USED GLP-1 Market: Distribution by Active Compound Used GLP-1 Market for Dulaglutide, till 2035 GLP-1 Market for liraglutide, till 2035 GLP-1 Market for Orforglipron, till 2035 GLP-1 Market for Retatrutide, till 2035 GLP-1 Market for Semaglutide, till 2035 GLP-1 Market for Survodutide, till 2035 GLP-1 Market for Tirzepatide, till 2035 GLP-1 Market for Other Active Compounds, till 2035 Data Triangulation and Validation GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS Chapter Overview Approved GLP-1 Drugs: Sales Forecast Feisumei (Benaglutide) Sales Forecast Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast Mounjaro (Tirzepatide) Sales Forecast Ozempic (Semaglutide Subcutaneous) Sales Forecast Rybelsus (Semaglutide Oral) Sales Forecast Saxenda (Liraglutide) Sales Forecast Trulicity (Dulaglutide) Sales Forecast Victoza (Liraglutide) Sales Forecast Wegovy (Semaglutide Subcutaneous) Sales Forecast XULTOPHY (Insulin Degludec / Liraglutide) Sales Forecast Zepbound (Tirzepatide) Sales Forecast Phase III GLP-1 Drugs: Sales Forecast GMA102 / Glutazumab Sales Forecast JY09 Sales Forecast LY3298176 / Tirzepatide Sales Forecast Mazdutide / LY3305677/ IBI-362 Sales Forecast Orforglipron / LY3502970 Sales Forecast PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast Retatrutide / LY3437943 Sales Forecast Semaglutide Oral Sales Forecast Semaglutide Subcutaneous Sales Forecast Survodutide / BI 456906 Sales Forecast XW003 / Ecnoglutide Sales Forecast YN011-isupaglutide Sales Forecast Companies Featured 4P-Pharma Adocia Alphamab Altimmune Amazon Amgen Arecor Therapeutics AstraZeneca Beijing Dongfang Biotech Shanghai Benemae Pharmaceutical Biocon Biolingus Biomm BNC KOREA Boehringer Ingelheim BrightGene Bio-Medical Technology Carmot Therapeutics Catalent Cipla Colorcon Ventures D&D Pharmatech DCP Capital Zhejiang Doer Biologics Dong-A Pharmaceutical Eccogene Eiger BioPharmaceuticals Eli Lilly Emisphere Technologies Entera Bio Flagship Pioneering Gan & Lee Pharmaceuticals Genexine Gmax Biopharm Hanmi Pharmaceutical Hansoh Pharma HK inno.N Huadong Medicine i2o Therapeutics IlDong Pharmaceutical ImmunoForge Innogen Invex Therapeutics Jiangsu Hengrui Pharmaceuticals Kariya Pharmaceuticals Kexing Biopharm LeaderMed Merck Metsera MindRank Mitsubishi Tanabe Pharma Nano Precision Medical Neuraly NeuroBo Pharmaceuticals Nexus Pharmaceuticals Novo Nordisk OPKO Health Oramed Pharmaceuticals PegBio Peptron Pfizer PROGEN Beijing QL Biopharmaceutica Rani Therapeutics Regor Pharmaceuticals Roche Sanofi Sciwind Biosciences SCOHIA PHARMA Second Sight Shanghai Minwei Biotechnology Shenzhen Salubris Pharmaceuticals Sino Biopharmaceutical Sinovac Biotech Structure Therapeutics Sun Pharmaceutical Terns Pharmaceuticals Tonghua Dongbao Pharmaceutical TRx Biosciences Uni-Bio Science United Laboratories Versanis Bio (acquired by Eli Lilly and Company) Viking Therapeutics Vivani Medical vTv Therapeutics Ypsomed Yuhan Zealand Pharma Additional Benefits Complimentary Excel Data Packs for all Analytical Modules in the Report 15% Free Content Customization Detailed Report Walkthrough Session with the Research Team Free Update if the Report is 6+ Months Old For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data
doi:10.1139/w06-043
Even with lower prices, there is little evidence to date to suggest that the expanded use of GLP-1s will be offset by lower spending on other health care services in the short term, even though the drugs do provide significant health benefits to users
The incompatibility is specifically with L-ascorbic acid - the conventional, water-soluble form of vitamin C used in most serums
